Rate My Professor Samantha Terry

Dr. Samantha Terry is a Reader in Radiobiology in the Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine at King’s College London. She leads the Radioactive Radiobiology laboratory, established in 2015, focusing on the radiobiology of targeted radionuclide therapies for cancer treatment. Her research investigates the effects of ionizing radiation from radionuclides on targeted tumor cells and off-target healthy cells, determines radiation dose-biological effect relationships, and explores strategies for optimal clinical use of radiopharmaceuticals. Studies are conducted primarily through in vitro cell models, in silico simulations, and preclinical approaches, including combination therapies with immunotherapy and external beam radiotherapy. Terry earned her PhD in X-ray radiobiology from the University of St Andrews between 2006 and 2009. Following her doctorate, she held postdoctoral positions at the University of Oxford’s Vallis lab (2009-2011, radionuclide therapy), Radboud University Medical Center in the Netherlands as a Roche Postdoctoral Research Fellow (2011-2014, radionuclide imaging), and King’s College London (2014-2015). At KCL, she advanced through the academic ranks: Lecturer from 2015 to 2021, Senior Lecturer from 2021 to 2023, and Reader since 2023.

Terry’s contributions include significant public engagement and outreach activities, for which she received the Royal Society of Biology Outreach and Engagement Award in 2018, recognizing her organization of the radioactivity in cancer exhibit at the Royal Society Summer Exhibition, training of over fifty volunteers, and talks to primary school children. She also won the Academy of Medical Sciences Springboard Award in 2016, providing funding and mentoring to establish her independent research program on radionuclide therapy assessment. Key publications encompass 'Radiobiology of molecular radiotherapy' (2019), 'Marshalling the Potential of Auger Electron Therapy' (2023), 'In vitro proof of concept studies of radiotoxicity from Auger electrons' (2021), 'The Power of Precision: Unravelling the Radiobiology of Targeted Radionuclide Therapy' (2025), 'Synthesis and characterisation of thallium-texaphyrin nanoparticles' (2024), and 'In Vitro and Preclinical Systematic Dose-Effect Studies of Auger Electron-Emitting 111In, 67Ga, 99mTc, and β Particle-Emitting Radionuclides' (2024). She serves on the editorial board of Nuclear Medicine and Biology and supervises PhD students on topics such as manganese-52 PET imaging and precision radiotherapy with immunotherapy.